We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+31.63%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.58B
AUM Growth
+$225M
Cap. Flow
+$66.3M
Cap. Flow %
4.18%
Top 10 Hldgs %
72.95%
Holding
32
New
8
Increased
10
Reduced
2
Closed
6

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$74.7M
2
EPZM
Epizyme, Inc
EPZM
+$38.9M
3
OMER icon
Omeros
OMER
+$30.6M
4
KDMN
Kadmon Holdings, Inc.
KDMN
+$29.3M
5
MYGN icon
Myriad Genetics
MYGN
+$28.6M

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$131M
2
LMNX
Luminex Corp
LMNX
+$55.5M
3
CORT icon
Corcept Therapeutics
CORT
+$30.6M
4
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$26M
5
PACB icon
Pacific Biosciences
PACB
+$18.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.53%
2 Miscellaneous 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
1
Amarin Corp
AMRN
$299M
$228M 14.4%
549,549
+77,011
+16% +$27.8M
UTHR icon
2
United Therapeutics
UTHR
$21.5B
$144M 9.08%
1,225,387
+124,790
+11% +$14.5M
PCRX icon
3
Pacira BioSciences
PCRX
$1.03B
$139M 8.77%
3,652,134
– –
QURE icon
4
uniQure
QURE
$3.15B
$118M 7.48%
1,985,460
+89,234
+5% +$3.99M
MYGN icon
5
Myriad Genetics
MYGN
$305M
$110M 6.94%
3,309,206
+938,910
+40% +$28.6M
TVTX icon
6
Travere Therapeutics
TVTX
$6.19B
$91.2M 5.76%
4,032,123
– –
CPRX
7
DELISTED
Catalyst Pharmaceutical
CPRX
$91.2M 5.75%
17,875,655
+8,473,338
+90% +$24.9M
AERI
8
DELISTED
Aerie Pharmaceuticals
AERI
$80.6M 5.09%
+1,696,773
New +$74.7M
VNDA icon
9
Vanda Pharmaceuticals
VNDA
$327M
$78.4M 4.95%
4,258,358
-400,401
-9% -$9.12M
VCEL icon
10
Vericel Corp
VCEL
$2B
$75.1M 4.74%
4,288,092
+70,000
+2% +$1.28M
URGN icon
11
UroGen Pharma
URGN
$2.15B
$65M 4.1%
1,759,324
+243,902
+16% +$10.2M
OXFD
12
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$44.9M 2.84%
2,608,784
+29,000
+1% +$459K
CORT icon
13
Corcept Therapeutics
CORT
$12.4B
$44M 2.78%
3,747,453
-2,464,511
-40% -$30.6M
EPZM
14
DELISTED
Epizyme, Inc
EPZM
$43.1M 2.72%
+3,478,261
New +$38.9M
OMER icon
15
Omeros
OMER
$1.39B
$36.9M 2.33%
+2,124,619
New +$30.6M
KDMN
16
DELISTED
Kadmon Holdings, Inc.
KDMN
$30.7M 1.94%
+11,627,900
New +$29.3M
KPTI icon
17
Karyopharm Therapeutics
KPTI
$39M
$30.1M 1.9%
343,926
+23,254
+7% +$2.58M
AUPH icon
18
Aurinia Pharmaceuticals
AUPH
$2.16B
$27.4M 1.73%
4,222,558
+4,212,558
+42,126% +$27.9M
CCXI
19
DELISTED
ChemoCentryx, Inc.
CCXI
$23.1M 1.46%
+1,666,667
New +$19.1M
SVRA icon
20
Savara
SVRA
$1.14B
$22.8M 1.44%
3,093,690
– –
ADMA icon
21
ADMA Biologics
ADMA
$2.14B
$17.4M 1.1%
4,588,352
– –
AKBA icon
22
Akebia Therapeutics
AKBA
$283M
$11.7M 0.74%
+1,430,579
New +$9.82M
IOVA icon
23
Iovance Biotherapeutics
IOVA
$3.95B
$10.8M 0.68%
+1,140,000
New +$11.1M
ANIP icon
24
ANI Pharmaceuticals
ANIP
$1.62B
$10.1M 0.64%
142,943
– –
IMMU
25
DELISTED
Immunomedics Inc
IMMU
$2.79M 0.18%
+145,000
New +$2.34M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, Consonance Capital Management held 32 positions worth $1.58B, up 17% from $1.36B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Consonance Capital Management deployed $66.3M of net new capital in Q1 2019, opening 8 new positions and adding to 10 existing holdings. Its largest new stake was Aerie Pharmaceuticals: 1,696,773 shares worth $80.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Corcept Therapeutics, an estimated $30.6M trimmed.

  • Consonance Capital Management's largest Q1 2019 buy was Aerie Pharmaceuticals: 1,696,773 shares worth $80.6M.
  • Consonance Capital Management added most to Myriad Genetics in Q1 2019, an estimated $28.6M increase.
  • Consonance Capital Management's biggest Q1 2019 reduction was Corcept Therapeutics, cutting an estimated $30.6M.
  • Consonance Capital Management fully exited Exelixis in Q1 2019, selling an estimated $131M.
  • Consonance Capital Management's ten largest holdings make up 73% of its $1.58B portfolio in Q1 2019.
  • Consonance Capital Management opened 8 new positions and closed 6 in Q1 2019.
  • Consonance Capital Management's portfolio value rose 17% quarter-over-quarter to $1.58B.

Based on Consonance Capital Management's 13F filing for Q1 2019, filed 15 May 2019.